REGENERON PHARMACEUTICALS, INC. Shareholders' Equity
REGENERON PHARMACEUTICALS, INC. (REGN) had Shareholders' Equity of $31.71 billion as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-30
- 2026-06-30: Stockholders' Equity Attributable to Parent $31.71B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $31.42B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $31.26B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $30.96B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $31.71B 10-Q · filed 2026-07-30 | |
| 2026-03-31 | $31.42B 10-Q · filed 2026-07-30 | |
| 2025-12-31 | $31.26B 10-Q · filed 2026-07-30 | |
| 2025-09-30 | $30.96B 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $29.94B 10-Q · filed 2026-07-30 | |
| 2025-03-31 | $29.39B 10-Q · filed 2026-07-30 | |
| 2024-12-31 | $29.35B 10-Q · filed 2026-07-30 | |
| 2024-09-30 | $29.33B 10-Q · filed 2025-10-28 | |
| 2024-06-30 | $28.21B 10-Q · filed 2025-10-28 | |
| 2024-03-31 | $26.99B 10-Q · filed 2025-10-28 | |
| 2023-12-31 | $25.97B 10-K · filed 2026-02-04 | |
| 2023-09-30 | $24.90B 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $24.02B 10-Q · filed 2024-10-31 | |
| 2023-03-31 | $23.50B 10-Q · filed 2024-10-31 | |
| 2022-12-31 | $22.66B 10-K · filed 2026-02-04 | |
| 2022-09-30 | $21.44B 10-Q · filed 2023-11-02 | |
| 2022-06-30 | $20.69B 10-Q · filed 2023-11-02 | |
| 2022-03-31 | $19.91B 10-Q · filed 2023-11-02 | |
| 2021-12-31 | $18.77B 10-K · filed 2025-02-05 | |
| 2021-09-30 | $17.26B 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $15.13B 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $11.98B 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $11.03B 10-K · filed 2024-02-05 | |
| 2020-09-30 | $10.13B 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $9.06B 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $12.13B 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $11.09B 10-K · filed 2023-02-06 | |
| 2019-09-30 | $10.50B 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $9.76B 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $9.44B 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $8.76B 10-K · filed 2022-02-07 | |
| 2018-09-30 | $7.87B 10-Q · filed 2019-11-05 | $7.87B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $7.19B 10-Q · filed 2019-11-05 | $7.19B 10-Q · filed 2018-08-02 |
| 2018-03-31 | $6.57B 10-Q · filed 2019-11-05 | $6.57B 10-Q · filed 2018-05-03 |
| 2017-12-31 | $6.14B 10-K · filed 2021-02-08 | $6.14B 10-K · filed 2018-02-08 |
| 2017-09-30 | $6.05B 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $5.52B 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $4.87B 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $4.45B 10-K · filed 2020-02-07 | $4.45B 10-K · filed 2017-02-09 |
| 2016-09-30 | $4.49B 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $4.08B 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $3.77B 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $3.65B 10-K · filed 2019-02-07 | $3.65B 10-K · filed 2016-02-11 |
| 2015-09-30 | $3.30B 10-Q · filed 2015-11-04 | |
| 2015-06-30 | $3.34B 10-Q · filed 2015-08-04 | |
| 2015-03-31 | $2.97B 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $2.55B 10-K · filed 2018-02-08 | $2.54B 10-K · filed 2015-02-12 |
| 2014-09-30 | $2.55B 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $2.37B 10-Q · filed 2014-08-05 | |
| 2014-03-31 | $2.21B 10-Q · filed 2014-05-08 | |
| 2013-12-31 | $1.96B 10-K · filed 2017-02-09 | $1.95B 10-K · filed 2014-02-13 |
| 2013-09-30 | $1.69B 10-Q · filed 2014-11-04 | |
| 2013-06-30 | $1.49B 10-Q · filed 2014-08-05 | |
| 2013-03-31 | $1.41B 10-Q · filed 2014-05-08 | |
| 2012-12-31 | $1.26B 10-K · filed 2016-02-11 | $1.25B 10-K · filed 2013-02-15 |
| 2012-09-30 | $806.02M 10-Q · filed 2013-11-05 | |
| 2012-06-30 | $594.66M 10-Q · filed 2013-08-06 | |
| 2012-03-31 | -$30.79M 10-Q · filed 2013-05-03 | $504.02M 10-Q · filed 2012-04-26 |
| 2011-12-31 | $485.73M 10-K · filed 2015-02-12 | |
| 2011-09-30 | $428.25M 10-Q · filed 2012-10-24 | |
| 2011-06-30 | $478.03M 10-Q · filed 2012-07-25 | |
| 2011-03-31 | $518.09M 10-Q · filed 2012-04-26 | |
| 2010-12-31 | $527.82M 10-K · filed 2014-02-13 | |
| 2010-09-30 | $348.06M 10-Q · filed 2011-10-27 | |
| 2010-06-30 | $371.22M 10-Q · filed 2011-07-28 | |
| 2010-03-31 | $386.27M 10-Q · filed 2011-05-03 | |
| 2009-12-31 | $396.76M 10-K · filed 2013-02-15 | |
| 2009-09-30 | $422.44M 10-Q · filed 2010-10-28 | |
| 2009-06-30 | $410.51M 10-Q · filed 2010-07-28 | |
| 2008-12-31 | $421.51M 10-K · filed 2012-02-21 | |
| 2007-12-31 | $459.35M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |